346 related articles for article (PubMed ID: 21486218)
1. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
2. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
3. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
Zhang C; Tan C; Ding H; Xin T; Jiang Y
Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
[TBL] [Abstract][Full Text] [Related]
4. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
5. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
Schenone S; Bondavalli F; Botta M
Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
10. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
11. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.
Baka S; Clamp AR; Jayson GC
Expert Opin Ther Targets; 2006 Dec; 10(6):867-76. PubMed ID: 17105373
[TBL] [Abstract][Full Text] [Related]
12. [VEGF and its receptors as therapeutic target in cancer therapy].
Gisterek I; Kornafel J
Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
[TBL] [Abstract][Full Text] [Related]
13. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Roodhart JM; Langenberg MH; Witteveen E; Voest EE
Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
FĂ©liz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
16. Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions.
Malekan M; Ebrahimzadeh MA
Curr Top Med Chem; 2022; 22(11):891-920. PubMed ID: 35260067
[TBL] [Abstract][Full Text] [Related]
17. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
Kiselyov A; Balakin KV; Tkachenko SE
Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
19. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
Underiner TL; Ruggeri B; Gingrich DE
Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
[TBL] [Abstract][Full Text] [Related]
20. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]